Invivyd Welcomes Dr. Paul B. Bolno to Board of Directors
Invivyd, Inc. today proudly announced the appointment of Paul B. Bolno, M.D., to its Board of Directors, as well as his position on the Compensation Committee. Dr. Bolno has been serving as the President and CEO of Wave Life Sciences since 2013, showcasing an impressive track record in the biotechnology sector.
Vision for Public Health
In a statement, Marc Elia, Chairman of the Board of Invivyd, expressed enthusiasm for Dr. Bolno's role during a pivotal period for the company. "We are happy to have Dr. Bolno join our Board at this critical moment while we transition toward a future focused on helping large populations avoid becoming ill from major viral infectious diseases," he said. His extensive experience in advancing Wave Life Sciences’ pipeline development will be instrumental as Invivyd strives to support public health initiatives.
Dr. Bolno's Expertise and Contributions
Dr. Bolno’s qualifications extend well beyond his role at Wave Life Sciences, where he has significantly contributed to developing innovative therapeutics. He also serves on the Board of Directors of ExpressionEdits and chairs the Scientific Advisory Group for the Nucleic Acid Therapy Accelerator, demonstrating his commitment to advancing healthcare through science and technology.
Commitment to Innovation
Upon joining Invivyd, Dr. Bolno stated, "I am honored to join the Board of Invivyd, as we share a sense of urgency to keep Americans healthy via our deep commitment to scientific excellence." He emphasized the importance of Invivyd’s unique capabilities to foster meaningful innovations in addressing viral infectious diseases, including COVID-19 and potentially Long COVID. Such advancements are necessary for modern healthcare challenges.
About Invivyd
Invivyd, Inc. is a biopharmaceutical company committed to providing protection against serious viral infectious diseases, particularly SARS-CoV-2. The company utilizes a proprietary, integrated technology platform that is unparalleled in the industry, designed for monitoring, assessing, and developing high-quality antibodies. Notably, Invivyd received emergency use authorization (EUA) from the U.S. FDA for one of its monoclonal antibody candidates in 2024, reflecting its commitment to innovative healthcare solutions.
Future Directions
As Invivyd moves forward, the company aims to expand its pipeline of innovative antibody therapies, which could significantly impact the treatment landscape for viral infections. Invivyd leverages its scientific expertise to adapt rapidly to the evolving healthcare environment, striving to provide effective preventive and therapeutic options for patients.
Frequently Asked Questions
What role is Dr. Paul B. Bolno taking on at Invivyd?
Dr. Bolno is appointed to the Board of Directors and also serves on the Compensation Committee.
What is the focus of Invivyd's work?
Invivyd concentrates on delivering innovative solutions for the prevention and treatment of serious viral infectious diseases.
How has Invivyd responded to recent health challenges?
Invivyd has developed monoclonal antibodies and gained emergency use authorization to help fight COVID-19 and other viral threats.
What is Dr. Bolno's background in healthcare?
Dr. Bolno has significant experience in biotechnology, previously leading Wave Life Sciences as its President and CEO.
How is Invivyd's platform unique?
Invivyd's integrated technology platform is designed specifically for creating and adapting antibodies, making it a leader in biopharmaceutical innovation.
